Industry News
Biotechnology Industry News
OSE Immunotherapeutics has shared…
OSE Immunotherapeutics has shared phase 2 data on its neo-epitope vaccine candidate and Keytruda in ovarian cancer, linking maintenance use of the combination to improvements over best supportive care.
A phase 2b trial of Biogen and…
A phase 2b trial of Biogen and Denali Therapeutics’ Parkinson’s disease candidate has missed its primary endpoint, prompting the partners to end development in the idiopathic form of the condition.
Stephen Hahn, M.D., who served as…
Stephen Hahn, M.D., who served as the commissioner of the FDA for just over a year during the first Trump administration, is taking his extensive regulatory expertise to Turn Therapeutics. As executive clinical and regulatory
Eli Lilly is laying the groundwork…
Eli Lilly is laying the groundwork for a phase 2 trial of the lipid-lowering gene editor it picked up from Verve Therapeutics, with the candidate now showing strong and consistent cholesterol reductions after a higher
As Eli Lilly looks to hold its…
As Eli Lilly looks to hold its lead in the lucrative obesity market, the company’s next-gen prospect, the triple-G drug retatrutide, has met the primary endpoint for weight loss in another pivotal study. Though the
Cancer immunotherapy company…
Cancer immunotherapy company Liminatus Pharma has agreed to pay out shares worth $320 million to buy CAR-T biotech InnocsAI.
Infex Therapeutics is pushing…
Infex Therapeutics is pushing ahead with development of a non-cystic fibrosis bronchiectasis drug candidate after posting phase 2a data, advancing efforts to add to the options for treating patients who recently gained access to Insmed’s
Several biotech contracts are…
Several biotech contracts are rotating through Kalshi and Polymarket, while a prediction market specifically focused on clinical trials has recently launched.
As an outbreak of Ebola in central…
As an outbreak of Ebola in central Africa continues to worsen, the federal government has tapped a little-known biotech in San Diego to provide doses of an experimental antibody that may be used to treat
To Roche, a phase 3 flop in…
To Roche, a phase 3 flop in first-line breast cancer does not erase the megablockbuster potential of its oral SERD drug giredestrant. Instead, the Swiss pharma has been inspired to open a new phase 3
San Carlos-based Engage is…
San Carlos-based Engage is developing non-viral DNA delivery systems that aim to overcome traditional limitations associated with the modality.
In the sprawling metropolis of…
In the sprawling metropolis of Houston, a new biotech has emerged to tackle the biology underlying a lung disease that has no clear cause. Oorja Bio launched yesterday afternoon with $30 million and an in-licensed,
Incyte is paying Genesis $80…
Incyte is paying Genesis $80 million upfront to expand use of its partner’s AI platform across a broader range of targets, continuing the biotech’s rapid embrace of AI in drug discovery and development.
Immunovant has confirmed that its…
Immunovant has confirmed that its first-generation FcRn inhibitor has been scrapped, a month after the asset flunked a pair of phase 3 eye disease trials.
With the ink barely dry on an…
With the ink barely dry on an antibody-drug conjugate-style deal with Regeneron, Parabilis Medicines has now turned its attention to the public markets.
After decades of developing…
After decades of developing vaccines to shield babies and adults from Streptococcus pneumonia infections, Pfizer is now taking another leap forward in its efforts to protect against one of the bacteria’s most dangerous strains—all while
Incyte and Edison Scientific have…
Incyte and Edison Scientific have signed a collaboration to employ Edison’s AI scientist, Kosmos, in Incyte’s drug discovery and development work.
Exelixis has secured supplies of…
Exelixis has secured supplies of subcutaneous Keytruda from Merck & Co. for a planned phase 3 study, completing the trio of contributors needed to run the colorectal cancer trial.
Relay Therapeutics’ R&D…
Relay Therapeutics’ R&D chief remains convinced the biotech’s PI3Kα inhibitor will carve out its own niche after reporting a slice of phase 2 data in patients with a type of blood vessel disorder.
Sanofi and Wave Life Sciences are…
Sanofi and Wave Life Sciences are using their time at the annual meeting of the American Thoracic Society in Orlando to share updated data for their next-gen attempts to treat a protein deficiency disorder that